PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS

por M., RAB, M., VAN DIJK, J., BOS, B., VAN OIRSCHOT, J., GERRITS, P., KOSINSKI, C., KUNG, J., JANS, E., VAN BEERS, L., DANG, R., VAN WIJK
Publicado 2022

PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE...

por M., VAN DIJK, M., RAB, B., VAN OIRSCHOT, J., BOS, C., DERICHS, A., RIJNEVELD, M., CNOSSEN, E., NUR, B., BIEMOND, M., BARTELS, J., JANS, W., VAN SOLINGE, R., SCHUTGENS, R., VAN WIJK, E., VAN BEERS
Publicado 2022

PI-04: OXYGEN GRADIENT EKTACYTOMETRY-DERIVED BIOMARKERS ARE ASSOCIATED WITH THE OCCURRENCE OF ACUTE COMPLICATIONS IN SICKLE CELL DISEASE

por M., RAB, C., KANNE, C., BOISSON, J., BOS, B., VAN OIRSCHOT, M., HOUWING, C., RENOUX, R., SCHUTGENS, M., BARTELS, A., RIJNEVELD, E., NUR, M., CNOSSEN, J., PHILIPPE, R., FORT, P., CONNES, R., VAN WIJK, V., SHEEHAN, E., VAN BEERS
Publicado 2022